Targeted Nanoparticle C’Dot Drug Conjugates, or CDCs, with Target or Clear™ capabilities, are designed to improve efficacy and reduce side effects. CDCs achieve this by selectively targeting and penetrating into tumors, binding to individual cancer cells where they are internalized and release their highly potent drug payloads inside targeted cancer cells.
Barney Yoo, Kai Ma, Li Zhang, Andrew Burns, Sonia Sequeira, Ingo Mellinghoff, Cameron Brennan, Ulrich Wiesner and Michelle S. Bradbury. Ultrasmall Dual-Modality Silica Nanoparticle Drug Conjugates: Design, Synthesis, and Characterization. Bioorg Med Chem. 2015 November 15; 23(22): 7119-7130
C’Dots have demonstrated exciting potential to deliver radioisotopes to tumors for both diagnostic and therapeutic applications.
Diagnostic: C’Dots can target PET radiotracers to tumors to facilitate greater precision of detection.
These are two PET-CT scans of the same melanoma-laden subject. The image on the left uses 18F-FDG, a current standard of care. The image on the right uses 124I-cRGDY-PEG-C-Dots. The authors noted the improved ability of C-Dots in discriminating cancer from inflammatory tissue.
M. S. Bradbury, E. Phillips, P. Montero Miranda, S. M. Cheala, H. Stambuk, J. C. Durack, C. T. Sofocleous, R. J. C. Meester, U. Wiesner, S. Patel, Clinically-Translated Silica Nanoparticles as Dual-Modality Cancer-Targeted Probes for Image-Guided Surgery and Interventions, Integr. Biol. 5 (2013), 74-86. Figure 8.
Therapeutic: targeted radiotherapeutic with the potential to offer enhanced outcomes alone or in combination with immunotherapy.
C’Dots Target or Clear™ capabilities provide an ideal combination of specific cancer cell targeting of a radiotherapeutic payload with rapid elimination from non-targeted healthy tissues. The rapid tumor-targeting of C’Dots provides the potential to be effective at delivering a wide range of radioisotope payloads ranging from beta-emitters with longer half-lives to extremely potent alpha-emitters with half-lives too short to be delivered by conventional antibody-based approaches.
The cancer-targeting properties of C’Dots combined with their fluorescent core creates a platform to support real-time detection of sites of disease and identification of tumor margins in the operating suite.